Intranasal apomorphine: a new treatment in Parkinson's disease.

  title={Intranasal apomorphine: a new treatment in Parkinson's disease.},
  author={R. Kapoor and N. Turjanski and J. Frankel and B. Kleedorfer and A. Lees and G. Stern and M. Bovingdon and R. Webster},
  journal={Journal of Neurology, Neurosurgery \& Psychiatry},
necessary to produce thermic dysregulation, whereas unilateral damage to the medulla oblongata appears to be sufficient.6 In our case, the initial downward gaze palsy indicates a bilateral involvement of the upper mesencephalon.7 This can be compared to Wernicke's encephalopathy where hypothermia may occur, and where the mesodiencephalic lesions, although more extended rostro-caudally, are bilateral.8 To our knowledge, no previous observation of hypothermia related to a mesodiencephalic lesion… Expand
Apomorphine in patients with Parkinson's disease.
Apomorphine test appears very useful for the differential diagnosis between idiopathic Parkinson's disease and other Parkinson plus syndromes, and as a predictive test for dopaminergic responsiveness, as well as a pharmacological tool for clinical research with the aim of a better understanding of the pathophysiology of Parkinson’s disease. Expand
Apomorphine in the treatment of Parkinson's disease: a review.
Apomorphine infusion therapy is compared with other treatments, such as oral therapy, deep brain stimulation and continuous enteral infusion of levodopa/carbidopa gel, and gives practical instructions on how to initiate treatment. Expand
The role of subcutaneous infusion of apomorphine in Parkinson’s disease
The evidence regarding efficacy, safety and tolerability of CSAI is summarized, guidance on the selection of suitable patients and practical instructions on how to initiate and manage possible adverse events are given. Expand
Efficacy of Intranasal Apomorphine in Parkinson's Disease
Intranasal apomorphine is a comfortable and easy alternative to subcutaneous apomorphicine in the treatment of off phases in patients with Parkinson's disease and severe refractory motor fluctuations. Expand
Apomorphine for Motor Fluctuations and Freezing in Parkinson's Disease
Apomorphine decreases off time, freezing, and levodopa requirements in patients with Parkinson's disease and recommendations for patient selection, product selection, and apomorphine dosing guidelines are presented. Expand
Rectal apomorphine: a new treatment modality in Parkinson's disease.
The evidence suggests that this patient with Munchausen's syndrome has repeatedly been admitted to hospital for investigation of acute headache and left hemiparesis and has undergone repeated radiological investigations and lumbar puncture. Expand
Paradoxical akinetic response to apomorphine in parkinsonism.
Sensory examination was normal, except for a small area on the top of the right shoulder, and a neuroma was suspected, but histology revealed a glomus tumour. Expand
Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up
Subcutaneous apomorphine is a highly effective treatment which can substantially improve the symptomatology in patients with advanced stage Parkinson’s disease over a prolonged period of time. Expand
Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease
  • F. Grandas
  • Medicine
  • Expert review of neurotherapeutics
  • 2013
The therapeutic effect of continuous apomorphine infusion is reviewed, practical recommendations on its use are provided and the patient's quality of life is improved. Expand
Intranasal apomorphine in parkinsonian on-off fluctuations.
The simplicity in the technique of intranasal apomorphine administration was found to be superior by all patients and the speed and the quality of motor response and the pharmacokinetic profile showed results similar to those seen after subcutaneous injection of apomorphicine administered by insulin pen syringe. Expand


Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.
It is proposed that the duration of response is primarily determined by levodopa peripheral pharmacokinetics rather than by central pharmacodynamic factors associated with dopamine storage capacity. Expand